[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse NUDT5

Summary
SymbolNUDT5
Namenudix (nucleoside diphosphate linked moiety X)-type motif 5
Aliases hYSAH1; YSA1H; YSA1; YSAH1; 8-oxo-dGDP phosphatase; Nudix motif 5; Nucleoside diphosphate-linked moiety X mo ......
Chromosomal Location10p14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF00293 NUDIX domain
Function

Enzyme that can either act as an ADP-sugar pyrophosphatase in absence of diphosphate or catalyze the synthesis of ATP in presence of diphosphate (PubMed:27257257). In absence of diphosphate, hydrolyzes with similar activities various modified nucleoside diphosphates such as ADP-ribose, ADP-mannose, ADP-glucose, 8-oxo-GDP and 8-oxo-dGDP (PubMed:10567213, PubMed:10722730, PubMed:19699693, PubMed:21389046, PubMed:17052728). Can also hydrolyze other nucleotide sugars with low activity (PubMed:19699693, PubMed:21389046). In presence of diphosphate, mediates the synthesis of ATP in the nucleus by catalyzing the conversion of ADP-ribose to ATP and ribose 5-phosphate. Nuclear ATP synthesis takes place when dephosphorylated at Thr-45 (PubMed:27257257). Nuclear ATP generation is required for extensive chromatin remodeling events that are energy-consuming (PubMed:27257257). Does not play a role in U8 snoRNA decapping activity (By similarity). Binds U8 snoRNA (By similarity).

> Gene Ontology
 
Biological Process GO:0005996 monosaccharide metabolic process
GO:0006014 D-ribose metabolic process
GO:0006338 chromatin remodeling
GO:0009116 nucleoside metabolic process
GO:0009119 ribonucleoside metabolic process
GO:0009123 nucleoside monophosphate metabolic process
GO:0009126 purine nucleoside monophosphate metabolic process
GO:0009132 nucleoside diphosphate metabolic process
GO:0009134 nucleoside diphosphate catabolic process
GO:0009141 nucleoside triphosphate metabolic process
GO:0009144 purine nucleoside triphosphate metabolic process
GO:0009150 purine ribonucleotide metabolic process
GO:0009161 ribonucleoside monophosphate metabolic process
GO:0009167 purine ribonucleoside monophosphate metabolic process
GO:0009185 ribonucleoside diphosphate metabolic process
GO:0009191 ribonucleoside diphosphate catabolic process
GO:0009199 ribonucleoside triphosphate metabolic process
GO:0009205 purine ribonucleoside triphosphate metabolic process
GO:0016052 carbohydrate catabolic process
GO:0019303 D-ribose catabolic process
GO:0019321 pentose metabolic process
GO:0019323 pentose catabolic process
GO:0019439 aromatic compound catabolic process
GO:0034655 nucleobase-containing compound catabolic process
GO:0034656 nucleobase-containing small molecule catabolic process
GO:0042278 purine nucleoside metabolic process
GO:0044270 cellular nitrogen compound catabolic process
GO:0044282 small molecule catabolic process
GO:0044723 single-organism carbohydrate metabolic process
GO:0044724 single-organism carbohydrate catabolic process
GO:0046034 ATP metabolic process
GO:0046128 purine ribonucleoside metabolic process
GO:0046365 monosaccharide catabolic process
GO:0046434 organophosphate catabolic process
GO:0046700 heterocycle catabolic process
GO:1901292 nucleoside phosphate catabolic process
GO:1901361 organic cyclic compound catabolic process
GO:1901657 glycosyl compound metabolic process
GO:1990966 ATP generation from poly-ADP-D-ribose
Molecular Function GO:0000287 magnesium ion binding
GO:0016779 nucleotidyltransferase activity
GO:0017110 nucleoside-diphosphatase activity
GO:0019144 ADP-sugar diphosphatase activity
GO:0030515 snoRNA binding
GO:0044715 8-oxo-dGDP phosphatase activity
GO:0047631 ADP-ribose diphosphatase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa00230 Purine metabolism
Reactome R-HSA-1430728: Metabolism
R-HSA-15869: Metabolism of nucleotides
R-HSA-2393930: Phosphate bond hydrolysis by NUDT proteins
Summary
SymbolNUDT5
Namenudix (nucleoside diphosphate linked moiety X)-type motif 5
Aliases hYSAH1; YSA1H; YSA1; YSAH1; 8-oxo-dGDP phosphatase; Nudix motif 5; Nucleoside diphosphate-linked moiety X mo ......
Chromosomal Location10p14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between NUDT5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolNUDT5
Namenudix (nucleoside diphosphate linked moiety X)-type motif 5
Aliases hYSAH1; YSA1H; YSA1; YSAH1; 8-oxo-dGDP phosphatase; Nudix motif 5; Nucleoside diphosphate-linked moiety X mo ......
Chromosomal Location10p14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of NUDT5 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.78 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolNUDT5
Namenudix (nucleoside diphosphate linked moiety X)-type motif 5
Aliases hYSAH1; YSA1H; YSA1; YSAH1; 8-oxo-dGDP phosphatase; Nudix motif 5; Nucleoside diphosphate-linked moiety X mo ......
Chromosomal Location10p14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of NUDT5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1960.429
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.2090.929
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1870.914
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.4150.241
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.090.957
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.8290.703
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1010.767
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1820.895
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0010.999
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0110.995
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.0120.997
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.2290.00242
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of NUDT5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolNUDT5
Namenudix (nucleoside diphosphate linked moiety X)-type motif 5
Aliases hYSAH1; YSA1H; YSA1; YSAH1; 8-oxo-dGDP phosphatase; Nudix motif 5; Nucleoside diphosphate-linked moiety X mo ......
Chromosomal Location10p14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NUDT5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolNUDT5
Namenudix (nucleoside diphosphate linked moiety X)-type motif 5
Aliases hYSAH1; YSA1H; YSA1; YSAH1; 8-oxo-dGDP phosphatase; Nudix motif 5; Nucleoside diphosphate-linked moiety X mo ......
Chromosomal Location10p14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NUDT5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NUDT5.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolNUDT5
Namenudix (nucleoside diphosphate linked moiety X)-type motif 5
Aliases hYSAH1; YSA1H; YSA1; YSAH1; 8-oxo-dGDP phosphatase; Nudix motif 5; Nucleoside diphosphate-linked moiety X mo ......
Chromosomal Location10p14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NUDT5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolNUDT5
Namenudix (nucleoside diphosphate linked moiety X)-type motif 5
Aliases hYSAH1; YSA1H; YSA1; YSAH1; 8-oxo-dGDP phosphatase; Nudix motif 5; Nucleoside diphosphate-linked moiety X mo ......
Chromosomal Location10p14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of NUDT5 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolNUDT5
Namenudix (nucleoside diphosphate linked moiety X)-type motif 5
Aliases hYSAH1; YSA1H; YSA1; YSAH1; 8-oxo-dGDP phosphatase; Nudix motif 5; Nucleoside diphosphate-linked moiety X mo ......
Chromosomal Location10p14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between NUDT5 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolNUDT5
Namenudix (nucleoside diphosphate linked moiety X)-type motif 5
Aliases hYSAH1; YSA1H; YSA1; YSAH1; 8-oxo-dGDP phosphatase; Nudix motif 5; Nucleoside diphosphate-linked moiety X mo ......
Chromosomal Location10p14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting NUDT5 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.